Pharmacologic treatments for covid-19 patients
Interferon kappa+TFF2 vs Standard care
This comparison will not be updated. Last search date 28 Feb, 2022.
To access all information :
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=101
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| ChiCTR2000030262 Fu W, EClinicalMedicine, 2020 Full text Commentary |
Public/non profit |
Interferon kappa+TFF2 |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in China | N=80 |
Some concerns Details |
|